Frankfurt - Delayed Quote EUR
PTC Therapeutics, Inc. (BH3.F)
42.80
+1.40
+(3.38%)
At close: 8:04:03 AM GMT+2
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 1.93M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| GOLDEN LEE SCOTT Officer | Sale at price 46.95 per share. | Direct | 42,114 | Apr 2, 2025 |
| PAUWELS ERIC Officer | Sale at price 55.19 - 58.31 per share. | Direct | 630,104 | Mar 17, 2025 |
| OKEY STEPHANIE S Director | Sale at price 54.00 per share. | Direct | 270,000 | Mar 13, 2025 |
| BOULDING MARK ELLIOTT Officer | Sale at price 53.23 - 53.31 per share. | Direct | 827,233 | Mar 12, 2025 |
| BOULDING MARK ELLIOTT Officer | Conversion of Exercise of derivative security at price 33.02 per share. | Direct | 512,503 | Mar 12, 2025 |
| BOULDING MARK ELLIOTT Officer | Sale at price 52.24 - 53.15 per share. | Direct | 4,003,305 | Mar 11, 2025 |
| BOULDING MARK ELLIOTT Officer | Conversion of Exercise of derivative security at price 25.69 - 33.02 per share. | Direct | 2,407,913 | Mar 11, 2025 |
| JACOBSON ALLAN STEVEN Director | Sale at price 51.52 per share. | Direct | 63,370 | Mar 4, 2025 |
| BOULDING MARK ELLIOTT Officer | Sale at price 50.10 - 50.12 per share. | Direct | 147,678 | Feb 20, 2025 |
| PAUWELS ERIC Chief Executive Officer | Sale at price 50.10 - 50.12 per share. | Direct | 147,577 | Feb 20, 2025 |
| ALMSTEAD NEIL GREGORY Chief Technology Officer | Sale at price 50.10 - 50.12 per share. | Indirect | 147,628 | Feb 20, 2025 |
| GOLDEN LEE SCOTT Officer | Sale at price 50.10 - 50.12 per share. | Direct | 88,046 | Feb 20, 2025 |
| UTTER CHRISTINE MARIE Officer | Sale at price 50.10 - 50.12 per share. | Direct | 88,043 | Feb 20, 2025 |
| KLEIN MATTHEW B Chief Executive Officer | Sale at price 50.10 - 50.12 per share. | Direct | 390,457 | Feb 20, 2025 |
| GRAVIER PIERRE Chief Financial Officer | Sale at price 50.10 - 50.12 per share. | Direct | 117,007 | Feb 20, 2025 |
| BOULDING MARK ELLIOTT Officer | Sale at price 44.50 - 45.34 per share. | Direct | 158,871 | Jan 8, 2025 |
| PAUWELS ERIC Chief Executive Officer | Sale at price 44.50 - 45.34 per share. | Direct | 167,551 | Jan 8, 2025 |
| ALMSTEAD NEIL GREGORY Chief Operating Officer | Sale at price 44.50 - 45.34 per share. | Indirect | 133,674 | Jan 8, 2025 |
| GOLDEN LEE SCOTT Officer | Sale at price 44.50 - 45.34 per share. | Direct | 90,036 | Jan 8, 2025 |
| UTTER CHRISTINE MARIE Officer | Sale at price 44.50 - 45.34 per share. | Direct | 132,493 | Jan 8, 2025 |
| KLEIN MATTHEW B Chief Executive Officer | Sale at price 44.50 - 45.34 per share. | Direct | 204,007 | Jan 8, 2025 |
| KLEIN MATTHEW B Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| SMITH MARY L Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| YOUNG ALETHIA R. Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| GRAVIER PIERRE Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| SOUTHWELL DAVID P Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| ZELDIS JEROME B. M.D., PH.D. Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| BOULDING MARK ELLIOTT Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| STEELE GLENN D JR Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| SCHMERTZLER MICHAEL Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| PAUWELS ERIC Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| ALMSTEAD NEIL GREGORY Chief Technology Officer | Stock Award(Grant) at price 0.00 per share. | Indirect | 0 | Jan 3, 2025 |
| JACOBSON ALLAN STEVEN Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| REEVE EMMA Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| GOLDEN LEE SCOTT Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| UTTER CHRISTINE MARIE Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| OKEY STEPHANIE S Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 3, 2025 |
| KLEIN MATTHEW B Chief Executive Officer | Sale at price 45.16 per share. | Direct | 373,880 | Dec 31, 2024 |
| BOULDING MARK ELLIOTT Officer | Sale at price 52.17 - 54.14 per share. | Direct | 5,022,334 | Dec 3, 2024 |
| BOULDING MARK ELLIOTT Officer | Conversion of Exercise of derivative security at price 33.02 - 51.00 per share. | Direct | 4,705,970 | Dec 3, 2024 |
| ZELDIS JEROME B. M.D., PH.D. Director | Sale at price 50.52 - 52.42 per share. | Direct | 1,235,897 | Dec 2, 2024 |
| ALMSTEAD NEIL GREGORY Chief Operating Officer | Sale at price 51.85 - 52.76 per share. | Indirect | 3,727,958 | Dec 2, 2024 |
| UTTER CHRISTINE MARIE Officer | Sale at price 51.34 - 52.45 per share. | Direct | 921,585 | Dec 2, 2024 |
| ZELDIS JEROME B. M.D., PH.D. Director | Conversion of Exercise of derivative security at price 30.86 - 51.00 per share. | Direct | 982,320 | Dec 2, 2024 |
| ALMSTEAD NEIL GREGORY Chief Operating Officer | Conversion of Exercise of derivative security at price 51.00 per share. | Indirect | 3,652,110 | Dec 2, 2024 |
| UTTER CHRISTINE MARIE Officer | Conversion of Exercise of derivative security at price 51.00 per share. | Direct | 907,800 | Dec 2, 2024 |
| GRAVIER PIERRE Chief Financial Officer | Sale at price 34.02 per share. | Direct | 77,200 | Jul 16, 2024 |
| ZELDIS JEROME B. M.D., PH.D. Director | Sale at price 38.24 per share. | Direct | 764,800 | May 22, 2024 |
| ZELDIS JEROME B. M.D., PH.D. Director | Conversion of Exercise of derivative security at price 26.42 per share. | Direct | 528,400 | May 22, 2024 |
| SOUTHWELL DAVID P Director | Stock Gift at price 0.00 per share. | Direct | 0 | May 8, 2024 |
Related Tickers
4DN.F Denali Therapeutics Inc.
12.88
+13.24%
BCAX Bicara Therapeutics Inc.
15.51
+12.23%
PHVS Pharvaris N.V.
14.82
-1.79%
MBX MBX Biosciences, Inc.
8.99
+4.05%
CNTA Centessa Pharmaceuticals plc
13.03
+2.84%
SRRK Scholar Rock Holding Corporation
32.52
+2.78%
XENE Xenon Pharmaceuticals Inc.
37.59
+2.34%
MRUS Merus N.V.
41.83
-3.19%
EPIX ESSA Pharma Inc.
1.7600
-1.12%
ACRV Acrivon Therapeutics, Inc.
2.0000
-1.48%